Melan-A inhibitors belong to a distinct chemical class characterized by their capacity to interact with and modulate the activity of the Melan-A protein. Melan-A, also known as MART-1 (Melanoma Antigen Recognized by T cells 1), is a melanocyte-specific protein expressed in the skin and other melanin-producing tissues. This protein plays a crucial role in melanin synthesis and pigmentation, which is responsible for the coloration of skin, hair, and eyes in humans. Melan-A inhibitors are designed to influence the function of this protein through various mechanisms, with the goal of manipulating melanin production for possible applications. Chemically, Melan-A inhibitors encompass a diverse range of compounds, often featuring unique structural motifs that allow them to selectively target and bind to specific regions of the Melan-A protein. These inhibitors can interfere with key enzymatic steps in the melanin synthesis pathway, thereby impacting the production of melanin pigments. Some inhibitors function by blocking the interaction between Melan-A and its substrate molecules, while others might inhibit downstream signaling pathways that contribute to melanin synthesis regulation. Researchers have explored the design and synthesis of Melan-A inhibitors in order to gain a deeper understanding of melanogenesis and its molecular underpinnings.
Given the pivotal role of Melan-A in melanin biosynthesis, inhibitors targeting this protein could offer valuable insights into the regulation of pigmentation processes and applications in various fields. Understanding the interactions between these inhibitors and the Melan-A protein can pave the way for novel approaches in the realm of skin biology and pigment-related research. Ongoing studies in this area continue to uncover the precise mechanisms through which Melan-A inhibitors influence melanin synthesis, contributing to the broader knowledge of pigmentation control and revealing new avenues for future scientific exploration.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
A BRAF kinase inhibitor used for melanomas with specific BRAF mutations. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Another BRAF inhibitor targeting certain BRAF mutations in melanoma. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor often combined with BRAF inhibitors for BRAF-mutated melanoma. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
A MEK inhibitor used in combination with BRAF inhibitors for melanoma. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
A MEK inhibitor used with encorafenib (a BRAF inhibitor) for unresectable or metastatic melanoma. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
A BRAF inhibitor used with binimetinib to target specific BRAF mutations in melanoma. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
A MEK inhibitor showing promise for neurofibromatosis type 1-related plexiform neurofibromas associated with melanoma. | ||||||